Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | IBI188 |
Synonyms | |
Therapy Description |
IBI188 (letaplimab) is an antibody against CD47 that binds to and blocks CD47 downstream signaling and subsequent activation of the SIRPa receptor on macrophages, potentially leading to phagocytosis of tumor cells, activation of cytotoxic T-cells (Blood (2022) 140 (Supplement 1): 4045-4046, NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
IBI188 | IBI-188|IBI 188|letaplimab | CD47 Antibody 31 | IBI188 (letaplimab) is an antibody against CD47 that binds to and blocks CD47 downstream signaling and subsequent activation of the SIRPa receptor on macrophages, potentially leading to phagocytosis of tumor cells, activation of cytotoxic T-cells (Blood (2022) 140 (Supplement 1): 4045-4046, NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03763149 | Phase I | IBI188 | A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188) in Patients With Advanced Malignant Tumors and Lymphomas | Completed | USA | 0 |